Skip to content
PubMed This is a summary of 17 peer-reviewed journal articles Updated
Hematology

Understanding Acquired Factor XIII Deficiency: Your First Steps

At a Glance

Acquired Factor XIII deficiency develops during life when Factor XIII is blocked by antibodies or consumed during serious medical events. It can cause delayed bleeding even when routine PT and aPTT results are normal, so specialized Factor XIII testing is needed.

Developing a severe bleeding disorder in adulthood can be a profound shock, especially when you have no previous personal or family history of easy bruising or bleeding. You may feel a sense of betrayal by your own body or a sudden loss of physical security. Understanding the mechanics of Factor XIII (FXIII) and how this condition differs from genetic bleeding disorders is often the first step toward regaining a sense of control.

The “Glue” of the Blood Clot

To understand Factor XIII, it helps to think of the blood-clotting process in two stages. First, your body creates a temporary “mesh” of fibrin to plug a wound. However, this initial mesh is fragile. Factor XIII is the enzyme that acts as the “molecular glue” to finish the job [1].

Specifically, Factor XIII performs three critical tasks to ensure you don’t bleed:

  • Cross-linking: It creates strong chemical bonds between fibrin strands, transforming a loose mesh into a stable, mechanical barrier that can withstand the pressure of blood flow [2][3].
  • Protection from Premature Breakdown: It “locks” protective proteins (antiplasmin) into the clot. This prevents your body’s natural clot-dissolving systems from breaking the plug down before the wound has actually healed [4][5].
  • Wound Healing: Beyond just stopping the bleeding, FXIII helps repair the tissue and supports the growth of new blood vessels [6][5].

When you have a Factor XIII deficiency, you can still form an initial clot, but that clot is “weak.” It often breaks down prematurely, leading to delayed bleeding—where a wound stops bleeding at first, only to start again hours or even days later [3].

Why This Happened Now: Understanding “Acquired”

If you have no prior history of bleeding, your condition is likely newly recognized or acquired, meaning it developed during your lifetime rather than being something you were born with. Mild congenital Factor XIII deficiency can sometimes present in adulthood, so your care team will use specific testing, and possibly clinical history and genetic evaluation, to confirm the diagnosis. This distinction is vital: unlike congenital (genetic) Factor XIII deficiency, an acquired condition is not something you will pass on to your children [7][8].

There are two primary ways an adult can develop this deficiency:

  1. Autoimmune (Immune-Mediated): This is the rarest form, occurring in approximately 0.044 cases per million people each year based on a Japanese registry [9]. In this version, your immune system mistakenly produces inhibitors (antibodies) that attack and neutralize your Factor XIII [10].
  2. Non-Immune (Consumptive): This is more common and often occurs during major medical events. Your body “uses up” its supply of Factor XIII faster than it can be replaced. This can happen during major surgery, severe infections (sepsis), or when using advanced life-support equipment like ECMO (extracorporeal membrane oxygenation) [11][12][13].

Validating Your Experience

It is common for patients with Factor XIII deficiency to feel unheard or frustrated during the initial diagnostic process. This is because routine coagulation tests—the standard blood panels like PT and aPTT—usually come back completely normal in people with this deficiency [7][14].

A diagnosis requires specialized testing, such as a quantitative FXIII activity assay, which measures how well your Factor XIII is working, or a mixing study to look for those immune system inhibitors [15][10]. If you felt that your symptoms were being overlooked because standard tests looked “fine,” your experience was medically valid: FXIII deficiency hides from standard screens.

Navigating the Emotional Impact

The suddenness of an acquired bleeding disorder can lead to significant anxiety and a reduced quality of life [16]. You may find yourself:

  • Fearing minor injuries or activities you previously enjoyed.
  • Feeling overwhelmed by the need for frequent medical monitoring or intravenous treatments [16].
  • Struggling to explain a “rare” condition to friends, family, or even other healthcare providers.

Recognizing that these feelings are a natural response to a major health shift is part of the healing process. While the condition is serious and an individual bleeding episode is an emergency, identifying the specific cause (whether immune or consumptive) allows your care team to tailor a management plan designed to stabilize your clotting and protect you from future bleeding events [17].

Common questions in this guide

What does acquired Factor XIII deficiency mean?
It means Factor XIII activity became low or was blocked during a person's lifetime rather than being present as an inherited condition from birth. Antibodies may neutralize Factor XIII, or serious medical events may consume it. Unlike congenital deficiency, an acquired condition is not something you pass to your children.
Why can my PT and aPTT be normal if I have a bleeding disorder?
Factor XIII strengthens the clot after the initial fibrin mesh forms, while routine PT and aPTT tests do not usually measure this final stabilizing step. These standard results can therefore be normal even when Factor XIII is not working well. A specialized Factor XIII activity assay is needed to evaluate it.
What can cause acquired Factor XIII deficiency?
There are two main patterns. An immune-mediated form occurs when antibodies block Factor XIII, while a non-immune consumptive form can occur when the body uses Factor XIII rapidly during major surgery, severe infection such as sepsis, or ECMO.
What bleeding signs should prompt urgent attention?
Watch for bleeding that returns hours or days after a wound or procedure seemed to stop, as well as unusual bleeding. Because a bleeding episode can be an emergency, seek urgent medical care rather than waiting for routine testing.
How is acquired Factor XIII deficiency confirmed?
A quantitative Factor XIII activity assay measures how well Factor XIII works. A mixing study may help identify an antibody inhibitor, and clinicians may also review personal and family history and consider genetic evaluation to distinguish acquired from congenital deficiency.
Why might I need evaluation at a specialized hematology center?
Acquired Factor XIII deficiency is uncommon and can be missed by routine coagulation tests, so hematology specialists can coordinate specialized testing and management. They can also help determine whether the problem is immune-mediated or consumptive.

Get notified when new evidence is published on Acquired factor XIII deficiency.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

References

References (17)
  1. 1

    The Plasma Factor XIII Heterotetrameric Complex Structure: Unexpected Unequal Pairing within a Symmetric Complex.

    Singh S, Nazabal A, Kaniyappan S, et al.

    Biomolecules 2019; (9(12)) doi:10.3390/biom9120765.

    PMID: 31766577
  2. 2

    Evaluating the Effects of Fibrinogen αC Mutations on the Ability of Factor XIII to Crosslink the Reactive αC Glutamines (Q237, Q328, Q366).

    Mouapi KN, Wagner LJ, Stephens CA, et al.

    Thrombosis and haemostasis 2019; (119(7)):1048-1057 doi:10.1055/s-0039-1687875.

    PMID: 31055797
  3. 3

    Elimination of fibrin γ-chain cross-linking by FXIIIa increases pulmonary embolism arising from murine inferior vena cava thrombi.

    Duval C, Baranauskas A, Feller T, et al.

    Proceedings of the National Academy of Sciences of the United States of America 2021; (118(27)) doi:10.1073/pnas.2103226118.

    PMID: 34183396
  4. 4

    Compaction of fibrin clots reveals the antifibrinolytic effect of factor XIII.

    Rijken DC, Abdul S, Malfliet JJ, et al.

    Journal of thrombosis and haemostasis : JTH 2016; (14(7)):1453-61 doi:10.1111/jth.13354.

    PMID: 27148673
  5. 5

    Coagulation factor XIII: a multifunctional transglutaminase with clinical potential in a range of conditions.

    Dickneite G, Herwald H, Korte W, et al.

    Thrombosis and haemostasis 2015; (113(4)):686-97 doi:10.1160/TH14-07-0625.

    PMID: 25652913
  6. 6

    Let's cross-link: diverse functions of the promiscuous cellular transglutaminase factor XIII-A.

    Mitchell JL, Mutch NJ

    Journal of thrombosis and haemostasis : JTH 2019; (17(1)):19-30 doi:10.1111/jth.14348.

    PMID: 30489000
  7. 7

    Factor XIII Deficiency: A Review of Biology, Testing, and Treatment.

    Jacobs JW, Booth GS, Costa V, et al.

    Clinical hematology international 2026; (8(1)):10-25 doi:10.46989/001c.155180.

    PMID: 41583548
  8. 8

    Diagnosis of factor XIII deficiency.

    Dorgalaleh A, Tabibian S, Hosseini MS, et al.

    Hematology (Amsterdam, Netherlands) 2016; (21(7)):430-9 doi:10.1080/10245332.2015.1101975.

    PMID: 27077776
  9. 9

    Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: A summary of 93 patients.

    Ichinose A,

    Blood reviews 2017; (31(1)):37-45 doi:10.1016/j.blre.2016.08.002.

    PMID: 27542511
  10. 10

    Immune-Related and Non-Immune-Related Acquired Factor XIII Deficiency.

    Ichinose A

    Seminars in thrombosis and hemostasis 2026; (52(3)):280-303 doi:10.1055/a-2633-0027.

    PMID: 40506046
  11. 11

    Measurement of factor XIII for the diagnosis and management of deficiencies: insights from a retrospective review of 10 years of data on consecutive samples and patients.

    Al Sharif MA, Mathews N, Tasneem S, et al.

    Research and practice in thrombosis and haemostasis 2025; (9(1)):102689 doi:10.1016/j.rpth.2025.102689.

    PMID: 40027442
  12. 12

    Acquired Factor XIII Deficiency Is Common during ECMO Therapy and Associated with Major Bleeding Events and Transfusion Requirements.

    Noitz M, Brooks R, Szasz J, et al.

    Journal of clinical medicine 2023; (12(12)) doi:10.3390/jcm12124115.

    PMID: 37373805
  13. 13

    Factor XIII Deficiency and Measurement.

    Hayward CPM, Mathews N

    Clinics in laboratory medicine 2026; (46(2)):185-198 doi:10.1016/j.cll.2026.02.012.

    PMID: 42140679
  14. 14

    Laboratory Diagnosis of Factor XIII Deficiency, Routine Coagulation Tests with Quantitative and Qualitative Methods.

    Dorgalaleh A, Kazemi A, Zaker F, et al.

    Clinical laboratory 2016; (62(4)):491-8 doi:10.7754/clin.lab.2015.150619.

    PMID: 27215067
  15. 15

    State of the art in factor XIII laboratory assessment.

    Durda MA, Wolberg AS, Kerlin BA

    Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 2018; (57(6)):700-704 doi:10.1016/j.transci.2018.07.006.

    PMID: 30087086
  16. 16

    Emicizumab for acquired hemophilia A: Report of two cases and dosing strategies.

    Ahmed F, Kasianchyk M, Moreno A, et al.

    EJHaem 2024; (5(2)):387-391 doi:10.1002/jha2.878.

    PMID: 38633111
  17. 17

    Acquired hemophilia A secondary to cholangiocarcinoma: A case report and literature review.

    Han X, Fu L, Li L, et al.

    Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 2025; (50(2)):275-280 doi:10.11817/j.issn.1672-7347.2025.240037.

    PMID: 40523770

This page is for informational purposes only and does not constitute medical advice. Your hematology team should interpret your Factor XIII test results and guide urgent care for any bleeding.